Page last updated: 2024-08-26

dihydroergocristine and Acute Confusional Senile Dementia

dihydroergocristine has been researched along with Acute Confusional Senile Dementia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fraering, PC; Lei, X; Liu, J; Niu, Q; Wu, F; Yu, J	1

Other Studies

1 other study(ies) available for dihydroergocristine and Acute Confusional Senile Dementia

Article	Year
The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-β peptides. Scientific reports, 2015, Nov-16, Volume: 5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Dihydroergocristine; Drug Approval; Drug Evaluation, Preclinical; HEK293 Cells; HeLa Cells; Humans; Protein Processing, Post-Translational; Receptors, Notch; Structure-Activity Relationship	2015

Article

Year

The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-β peptides.

Scientific reports, 2015, Nov-16, Volume: 5

Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Dihydroergocristine; Drug Approval; Drug Evaluation, Preclinical; HEK293 Cells; HeLa Cells; Humans; Protein Processing, Post-Translational; Receptors, Notch; Structure-Activity Relationship

2015